Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T in Adult Refractory/Recurrent T-cell Lymphoma/Leukemia
NCT05620680Recruiting
- Sponsor
- Shenzhen University General Hospital
- Start
- Oct 2022
- Primary completion
- Oct 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of UTAA07 in T-cell lymphoma and T-cell leukemia, sponsored by Shenzhen University General Hospital. Primary endpoint: Treatment-Emergent Adverse Events at 30 days. Started Oct 2022; status: recruiting.
02
Drugs
UTAA07
03
Conditions
T-cell lymphomaT-cell leukemia
Beyond the preview
Go deeper on NCT05620680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620680.